title: Evaluation of hydro-alcoholic extract of Eclipta alba for its anticancer potential: an in vitro study.
abstract: BACKGROUND
  Eclipta alba is traditionally used as hepatoprotective agent. The study was designed to explore its antiproliferative activity on liver and other related cancer.
  
  
  OBJECTIVE
  The present study was designed to assess and establish the role of Eclipta alba as anti-cancer agent using HepG2, C6 glioma and A498 cell lines as model system.
  
  
  METHODS
  Antiproliferative and cytotoxic effects of the Eclipta alba hydroalcoholic extract (EAE) was determined using MTT assay. The expression level of NF-kB was analysed by western blotting and RT PCR. Gelatin zymography was done for gelatinase matrix metalloproteinases (MMP-2 and 9) analysis.
  
  
  RESULTS
  EAE inhibited the cell proliferation in dose dependent manner in HepG2, A498 and C6 glioma cell lines with an IC50 of 22±2.9, 25±3.6 and 50±8.7 μg/ml, respectively. The expression of MMP (2 and 9) was down-regulated with EAE treatment. DNA damage was observed following 72h of extract treatment, leading to apoptosis. Additionally, the expression level of NF-kB was evaluated with western blotting and RT-PCR and was found to be down-regulated/inactivated.
  
  
  CONCLUSIONS
  The data establish the existence of anti-proliferative, DNA damaging and anti-metastasis properties in EAE which is yet unexplored and hold high therapeutic impact.
authors.affiliation: Institute of Science, Nirma University, Sarkhej-Gandhinagar Highway, Village - Chharodi, Ahmedabad, Gujarat 382481, India.
authors.forename: Harshita
authors.initials: H
authors.lastname: Chaudhary
authors.forename: Vikram
authors.initials: V
authors.lastname: Dhuna
authors.forename: Jatinder
authors.initials: J
authors.lastname: Singh
authors.forename: Sukhdev Singh
authors.initials: SS
authors.lastname: Kamboj
authors.forename: Sriram
authors.initials: S
authors.lastname: Seshadri
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004249:DNA Damage; D015536:Down-Regulation; D036601:Eclipta; D005910:Glioma / Q000188:drug therapy / Q000378:metabolism; D056945:Hep G2 Cells; D018197:Hepatoblastoma / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D020128:Inhibitory Concentration 50; D008113:Liver Neoplasms / Q000188:drug therapy / Q000378:metabolism; D020782:Matrix Metalloproteinases / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D018515:Plant Leaves
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D016328:NF-kappa B; D010936:Plant Extracts; D020782:Matrix Metalloproteinases